ClinicalGW Pharmaceuticals gets MHRA approval for Epidiolex to treat...

GW Pharmaceuticals gets MHRA approval for Epidiolex to treat TSC related seizures

-

A cannabinoid therapeutics developer and part of Jazz Pharmaceuticals plc., GW Pharmaceuticals, on August 10th, 2021, has announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for its drug, Epidiolex (cannabidiol), for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC) in the patients of age two and above.

Epidiolex helps treat seizures, which is an oral solution consisting of highly purified cannabidiol. Exceptional results yielded from the safety and efficacy data obtained from the phase III trials carried out by the European Commission Decision Reliance Procedure (ECDRP), paved way for the approval of the drug. 49% reduction in seizures had been noted among the patients using the said treatment. On the other hand, only 27% reduction was observed in the placebo group.

In different organs including brain, skin, kidneys, heart and eyes, the growth of benign tumors is usually caused by a rare genetic condition known as TSC, the severity of which can vary considerably. So according to the company, it has been a leading cause of the genetic epilepsy.

Louise Fish, Chief Executive Officer of Tuberous Sclerosis Association (TSA), said, “One in every two people living with TSC-related epileptic seizures has difficult to treat epilepsy that does not respond to traditional anti-epileptic drug.”

He further added, “We are excited to see this new medicine approved by the MHRA, which gives people living with TSC and their families hope. We desperately need further options for clinicians who are managing seizures associated with TSC, and we therefore welcome this decision by MHRA.”

Life Sciences Voice Logo mobile
+ posts

Latest news

Revolution Challenges Erasca’s ERAS-0015 Over Patent and Data Comparison Claims

Revolution Medicines has raised legal and competitive concerns against Erasca following recent developments in pancreatic cancer drug research. The...

Lilly and Profluent Sign Up to $2.25 Billion Collaboration to Develop AI-Designed Genetic Medicines

Eli Lilly has entered into a multi-program research collaboration with California-based Profluent to develop genetic medicines using artificial intelligence-designed...

Novartis and PTC Advance Huntington’s Drug Votoplam to Phase 3 Following Mid-Stage Data

Novartis and PTC Therapeutics have moved their Huntington’s disease candidate, votoplam, into Phase 3 development after results from a...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you